GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jazz Pharmaceuticals JAZZ · USD

Health Care · US listing · 🇺🇸 United States

Compare

243.55

+3.74%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$4.27bn

FY2016FY2025

Net income

−$356.1m

FY2016FY2025

Free cash flow

$1.15bn

FY2016FY2025

Shareholders' equity

$4.32bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$4.27bn$4.07bn$3.83bn$3.66bn$3.09bn$2.36bn$2.16bn$1.89bn$1.62bn$1.49bn
Gross profit$3.76bn$3.62bn$3.40bn$3.12bn$2.65bn$2.21bn$2.03bn$1.77bn$1.51bn$1.38bn
Research and development$782.7m$884.0m$849.7m$590.5m$505.7m$335.4m$299.7m$226.6m$198.4m$162.3m
Operating income$224.4m$716.6m$578.6m−$65.5m$170.3m$378.1m$532.4m$614.8m$528.8m$591.7m
Net income−$356.1m$560.1m$414.8m−$224.1m−$329.0m$238.6m$523.4m$447.1m$487.8m$396.8m
Diluted earnings per share-5.849.115.95-3.55-5.354.179.147.407.976.50

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$11.66bn$12.01bn$11.39bn$10.84bn$12.30bn$6.54bn$5.54bn$5.20bn$5.12bn$4.80bn
Cash and short-term investments$2.44bn$2.99bn$1.63bn$881.5m$591.4m$2.13bn$1.08bn$824.6m$601.0m$426.0m
Total liabilities$7.34bn$7.92bn$7.66bn$7.75bn$8.33bn$2.88bn$2.43bn$2.45bn$2.41bn$2.92bn
Debt$5.37bn$6.11bn$5.72bn$5.73bn$6.06bn$2.10bn$1.61bn$1.60bn$1.58bn$2.03bn
Shareholders' equity$4.32bn$4.09bn$3.74bn$3.09bn$3.97bn$3.66bn$3.11bn$2.76bn$2.71bn$1.88bn
Shares outstanding61m62m70m63m62m57m57m60m61m61m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$1.36bn$1.40bn$1.09bn$1.27bn$778.5m$899.6m$776.4m$798.9m$693.1m$590.5m
Capital spending−$209.8m−$48.1m−$24.0m−$498.2m−$45.5m−$379.3m−$182.3m−$131.5m−$114.0m−$181.6m
Free cash flow$1.15bn$1.35bn$1.07bn$773.8m$733.0m$520.4m$594.1m$667.4m$579.1m$409.0m
Dividends paid———−$98.0m−$99.7m−$99.7m−$57.8m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.21bn$1.07bn$1.20bn$1.13bn$1.05bn$897.8m$1.09bn$1.05bn
Gross profit$1.09bn$762.5m$1.17bn$868.3m$929.4m$793.2m$959.5m$943.4m
Operating income$248.2m$253.7m$909.2m$57.6m−$688.2m−$55.9m$190.8m$260.2m
Net income$192.8m$293.1m$203.5m$251.4m−$718.5m−$92.5m$191.1m$215.1m
Diluted earnings per share2.784.223.344.12-11.78-1.523.113.50
Cash from operations$415.0m$408.0m$362.0m$474.0m$88.0m$429.0m$398.0m$398.0m
Capital spending−$18.0m−$19.0m−$65.0m−$15.0m−$12.0m−$38.0m−$13.0m−$10.0m
Free cash flow$397.0m$389.0m$297.0m$459.0m$76.0m$391.0m$385.0m$388.0m
Total assets$11.08bn$11.86bn$11.66bn$11.36bn$10.94bn$11.53bn$12.01bn$12.26bn
Cash and short-term investments$2.20bn$2.87bn$2.44bn$2.05bn$1.67bn$2.57bn$2.99bn$2.62bn
Debt$4.37bn$5.37bn$5.37bn$5.38bn$5.38bn$5.38bn$6.12bn$6.13bn
Shareholders' equity$4.80bn$4.53bn$4.32bn$3.96bn$3.71bn$4.17bn$4.09bn$4.17bn

Financial ratios

Data as of 5 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin88.2%89.0%88.6%85.2%85.8%93.7%
Operating margin5.3%17.6%15.1%-1.8%5.5%16.0%
Net margin-8.3%13.8%10.8%-6.1%-10.6%10.1%
Return on equity-8.2%13.7%11.1%-7.3%-8.3%6.5%
Return on assets-3.1%4.7%3.6%-2.1%-2.7%3.7%
Free cash flow yield10.9%10.0%6.8%11.9%5.7%9.5%
Revenue growth4.9%6.1%4.8%18.3%30.9%9.3%
Earnings growth-163.6%35.0%-285.1%-31.9%-237.9%-54.4%
Current ratio1.86x4.46x2.24x2.79x3.23x4.34x
Debt to equity1.24x1.50x1.53x1.86x1.53x0.58x
Equity ratio37.0%34.1%32.8%28.5%32.2%56.0%
Interest coverage1.15x3.01x2.00x-0.23x0.61x3.79x
R&D as a share of sales18.3%21.7%22.2%16.1%16.3%14.2%
Buybacks as a share of market value0.8%11.7%-10.5%-2.5%-7.6%0.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.3%12.5%12.4%
Operating income—-9.9%-7.8%
Net income16.7%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin88.6%87.8%88.2%89.6%
Operating margin11.3%9.2%9.4%16.0%
Net margin2.4%2.5%1.4%8.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-29.113.520.7-44.8-23.839.516.316.816.916.8
Price to sales2.41.92.22.72.54.04.04.05.14.5

Market value over time

30 Nov 2016 to 2 Oct 2026, in USD

$6.40bn$16.36bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return36%-0%-22%24%-16%-2%17%-0%22%-21%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 18 Jan 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.